Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
GANX Gain Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: GANX
Price (delayed)
$1.99
Market cap
$58.82M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.86
Enterprise value
$50.36M
Gain Therapeutics, Inc. is redefining drug discovery with its See-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new
Highlights
The EPS has grown by 43% YoY and by 3.4% from the previous quarter
Gain Therapeutics's debt has decreased by 32% YoY and by 7% QoQ
GANX's equity is down by 33% year-on-year and by 21% since the previous quarter
GANX's quick ratio is down by 32% QoQ and by 29% YoY
Key stats
What are the main financial stats of GANX
Market
Valuations
Earnings
Shares outstanding
29.56M
Market cap
$58.82M
Enterprise value
$50.36M
Price to earnings (P/E)
N/A
Price to book (P/B)
9.57
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$20.34M
Net income
-$20.93M
EBIT
-$20.31M
EBITDA
-$20.23M
Free cash flow
-$19.13M
Per share
Balance sheet
Liquidity
EPS
-$0.86
EPS diluted
-$0.86
Free cash flow per share
-$0.67
Book value per share
$0.21
Revenue per share
$0
TBVPS
$0.4
Total assets
$11.62M
Total liabilities
$5.84M
Debt
$606,860
Equity
$5.78M
Working capital
$6.12M
Debt to equity
0.1
Current ratio
2.22
Quick ratio
1.8
Net debt/EBITDA
0.42
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-146.1%
Return on equity
-247.6%
Return on invested capital
N/A
Return on capital employed
-307.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GANX stock price
How has the Gain Therapeutics stock price performed over time
Intraday
-1%
1 week
10.56%
1 month
-3.4%
1 year
-18.78%
YTD
-7.87%
QTD
4.19%
Financial performance
How have Gain Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$20.34M
Net income
-$20.93M
Gross margin
N/A
Net margin
N/A
GANX's operating income is up by 4.9% YoY
The net income is down by 2.5% since the previous quarter
Price vs fundamentals
How does GANX's price correlate with its fundamentals
Growth
What is Gain Therapeutics's growth rate over time
Valuation
What is Gain Therapeutics stock price valuation
P/E
N/A
P/B
9.57
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 43% YoY and by 3.4% from the previous quarter
The stock's price to book (P/B) is 145% more than its 5-year quarterly average of 3.9 and 60% more than its last 4 quarters average of 6.0
GANX's equity is down by 33% year-on-year and by 21% since the previous quarter
Efficiency
How efficient is Gain Therapeutics business performance
Gain Therapeutics's return on equity has decreased by 16% YoY and by 11% QoQ
GANX's return on assets is down by 13% year-on-year and by 8% since the previous quarter
Dividends
What is GANX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GANX.
Financial health
How did Gain Therapeutics financials performed over time
GANX's total assets is 99% greater than its total liabilities
GANX's quick ratio is down by 32% QoQ and by 29% YoY
GANX's current ratio is down by 25% since the previous quarter and by 20% year-on-year
Gain Therapeutics's debt is 90% lower than its equity
GANX's equity is down by 33% year-on-year and by 21% since the previous quarter
Gain Therapeutics's debt has decreased by 32% YoY and by 7% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.